Absence of SHIV infection in gut and lymph node tissues in rhesus monkeys after repeated rectal challenges following HIV-1 DNA/MVA immunizations
- PMID: 17688978
- DOI: 10.1016/j.vaccine.2007.06.014
Absence of SHIV infection in gut and lymph node tissues in rhesus monkeys after repeated rectal challenges following HIV-1 DNA/MVA immunizations
Abstract
We reported previously the absence of systemic infection in a subset of macaques vaccinated with an HIV-1 DNA/MVA vaccine after 18 or more rectal challenges with low (physiologically relevant) doses of SHIV162P3. To further study the apparent protection, we looked for sequestered virus in gut tissues, lymph nodes, spleen, and testes obtained at necropsy using virus co-culture and nested PCR for SIV Gag, Pol and LTR. There was no evidence of sequestered virus in tissues obtained from the four protected macaques. In contrast, at least one tissue from each of 11 infected animals scored positive by one of these sensitive procedures. Activated PBMC from the protected macaques were not inherently resistant to in vitro infection by the challenge virus. These findings demonstrate that some vaccinated macaques appeared to be free from the challenge virus. Therefore, such T cell-based vaccines may provide some protection when challenge virus doses approach physiological equivalencies.
Similar articles
-
Protection from immunodeficiency virus challenges in rhesus macaques by multicomponent DNA immunization.Virology. 2001 Jul 5;285(2):204-17. doi: 10.1006/viro.2001.0958. Virology. 2001. PMID: 11437655
-
Multi-envelope HIV-1 vaccine devoid of SIV components controls disease in macaques challenged with heterologous pathogenic SHIV.Vaccine. 2005 Nov 16;23(46-47):5306-20. doi: 10.1016/j.vaccine.2005.07.008. Epub 2005 Jul 20. Vaccine. 2005. PMID: 16095768
-
Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope.AIDS. 2008 Jan 30;22(3):339-48. doi: 10.1097/QAD.0b013e3282f3ca57. AIDS. 2008. PMID: 18195560
-
Immune mechanisms associated with protection from vaginal SIV challenge in rhesus monkeys infected with virulence-attenuated SHIV 89.6.J Med Primatol. 2005 Oct;34(5-6):271-81. doi: 10.1111/j.1600-0684.2005.00125.x. J Med Primatol. 2005. PMID: 16128922 Review.
-
HIV vaccine design: insights from live attenuated SIV vaccines.Nat Immunol. 2006 Jan;7(1):19-23. doi: 10.1038/ni1296. Nat Immunol. 2006. PMID: 16357854 Review.
Cited by
-
Generation and evaluation of clade C simian-human immunodeficiency virus challenge stocks.J Virol. 2015 Feb;89(4):1965-74. doi: 10.1128/JVI.03279-14. Epub 2014 Dec 3. J Virol. 2015. PMID: 25473043 Free PMC article.
-
Short communication: Viremic control is independent of repeated low-dose SHIVSF162p3 exposures.AIDS Res Hum Retroviruses. 2014 Nov;30(11):1125-9. doi: 10.1089/aid.2014.0238. Epub 2014 Oct 14. AIDS Res Hum Retroviruses. 2014. PMID: 25313448 Free PMC article.
-
Susceptibility to repeated, low-dose, rectal SHIVSF162P3 challenge is independent of TRIM5 genotype in rhesus macaques.AIDS Res Hum Retroviruses. 2013 Jul;29(7):1091-4. doi: 10.1089/aid.2012.0383. Epub 2013 Mar 29. AIDS Res Hum Retroviruses. 2013. PMID: 23461569 Free PMC article.
-
Relevance of long-lived CD8(+) T effector memory cells for protective immunity elicited by heterologous prime-boost vaccination.Front Immunol. 2012 Dec 4;3:358. doi: 10.3389/fimmu.2012.00358. eCollection 2012. Front Immunol. 2012. PMID: 23264773 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
